TY - JOUR

T1 - Markers for cardiovascular disease in monozygotic twins discordant for the use of third-generation oral contraceptives

AU - Loos, R J F

AU - Verhaeghe, J

AU - De Zegher, F

AU - Beunen, G

AU - Derom, C

AU - Fagard, R

AU - Mathieu, C

AU - Vlietinck, R

PY - 2003/7

Y1 - 2003/7

N2 - Oral contraceptives (OC) modulate the risk for developing cardiovascular (CV) diseases. The aim of this study was to determine whether the use of third-generation OC has an impact on markers of CV disease in genetically identical women. We performed an intrapair comparison in 27 monozygotic twin pairs, one of whom was taking third-generation OC, whereas the other was not using OC. Biometric parameters were ascertained and conventional and 24-h ambulatory blood pressure (BP) was recorded. A fasting blood sample was taken for the measurement of glucose, insulin, proinsulin, lipids, and insulin-like growth factor binding protein-1 (IGFBP-1). Insulin resistance and beta-cell function were calculated by homeostasis model assessment (HOMA). A 24-h urine sample for cortisol was obtained. Third-generation OC use increased 24-h ambulatory systolic and diastolic BP by 5.2 and 3.9 mmHg, respectively (both P=0.0003). There was no effect on glucose, insulin and proinsulin levels, and on HOMA parameters, but the IGFBP-1 levels were markedly raised (P=0.0009). The lipid profile showed a 34% increase in triglyceride levels (P < 0.0001), but also a 7% increase in HDL-cholesterol levels (P=0.037). Use of third-generation OC impacts on CV disease markers in young-adult genetically identical women. Some changes are beneficial (increased HDL-cholesterol), whereas others may be deleterious (increased BP and triglyceride levels) or have unknown effects at this time (increased IGFBP-1 levels).

AB - Oral contraceptives (OC) modulate the risk for developing cardiovascular (CV) diseases. The aim of this study was to determine whether the use of third-generation OC has an impact on markers of CV disease in genetically identical women. We performed an intrapair comparison in 27 monozygotic twin pairs, one of whom was taking third-generation OC, whereas the other was not using OC. Biometric parameters were ascertained and conventional and 24-h ambulatory blood pressure (BP) was recorded. A fasting blood sample was taken for the measurement of glucose, insulin, proinsulin, lipids, and insulin-like growth factor binding protein-1 (IGFBP-1). Insulin resistance and beta-cell function were calculated by homeostasis model assessment (HOMA). A 24-h urine sample for cortisol was obtained. Third-generation OC use increased 24-h ambulatory systolic and diastolic BP by 5.2 and 3.9 mmHg, respectively (both P=0.0003). There was no effect on glucose, insulin and proinsulin levels, and on HOMA parameters, but the IGFBP-1 levels were markedly raised (P=0.0009). The lipid profile showed a 34% increase in triglyceride levels (P < 0.0001), but also a 7% increase in HDL-cholesterol levels (P=0.037). Use of third-generation OC impacts on CV disease markers in young-adult genetically identical women. Some changes are beneficial (increased HDL-cholesterol), whereas others may be deleterious (increased BP and triglyceride levels) or have unknown effects at this time (increased IGFBP-1 levels).

KW - Adult

KW - Biomarkers

KW - Blood Glucose/analysis

KW - Blood Pressure

KW - Blood Pressure Monitoring, Ambulatory

KW - Cardiovascular Diseases/chemically induced

KW - Contraceptives, Oral, Combined/adverse effects

KW - Diseases in Twins

KW - Female

KW - Humans

KW - Hydrocortisone/urine

KW - Insulin/blood

KW - Insulin Resistance

KW - Insulin-Like Growth Factor Binding Protein 1/blood

KW - Lipids/blood

KW - Progestins/adverse effects

KW - Proinsulin/blood

KW - Twins, Monozygotic

U2 - 10.1038/sj.jhh.1001578

DO - 10.1038/sj.jhh.1001578

M3 - Journal article

C2 - 12821955

VL - 17

SP - 481

EP - 485

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 7

ER -